Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment

Controlled inhibition of drug-metabolizing cytochrome P450 3A4 (CYP3A4) is utilized to boost bioavailability of anti-viral and immunosuppressant pharmaceuticals. We investigate structure–activity relationships (SARs) in analogues of ritonavir, a potent CYP3A4 inhibitor marketed as pharmacoenhancer,...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuels, Eric R., Sevrioukova, Irina F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266530/
https://www.ncbi.nlm.nih.gov/pubmed/35806297
http://dx.doi.org/10.3390/ijms23137291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266530/
https://www.ncbi.nlm.nih.gov/pubmed/35806297
http://dx.doi.org/10.3390/ijms23137291

Ejemplares similares